MDGL - Madrigal Pharmaceuticals, Inc.
About Madrigal Pharmaceuticals, Inc. (https://www.madrigalpharma.com)
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| William J. Sibold | Chief Executive Officer, President & Director | 1966 | $2,371,345 USD |
| Rebecca A. Taub | Founder, Senior Scientific & Medical Advisor and Director | 1952 | $1,222,044 USD |
| Mardi C. Dier | Executive Vice President & Chief Financial Officer | 1964 | $1,209,553 USD |
| Carole Huntsman | Executive Vice President & Chief Commercial Officer | 1965 | $1,079,128 USD |
| David Soergel | Executive VP & Chief Medical Officer | 1968 | $1,077,282 USD |
| Shannon Kelley | Executive Vice President, Chief Legal Officer & Corporate Secretary | 1975 | $1,073,105 USD |
| Mark Underwood | Executive Vice President of Business Planning & Operations | – | – |
| Rita Thakkar | Senior VP & Chief Accounting Officer | 1974 | – |
| Ronald Filippo | Executive Vice President & Chief Information Officer | – | – |
| Tina E. Ventura | Chief Investor Relations Officer | – | – |